Release Details
PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award
"I am honored to receive the 2014 Legend of Technology Award," stated
The 2014 New Jersey TechCouncil (NJTC) Awards Celebration honors the region's top technology companies and their leaders for their business accomplishments in technological collaboration, partnership and innovation. Each year the
According to
About
The mission of the
- Offer opportunities to network and collaborate;
- Provide access to financing sources;
- Recognize and promote technological innovation and accomplishment;
- Offer educational resources and professional development opportunities; and
- Advocate for the tech, innovation and entrepreneurial communities.
Founded in 1996,
About
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. PTC has received conditional marketing authorization in the European Economic Area for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients
aged five years and older. Translarna is an investigational new drug in
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact, contained in this release, including statements regarding the future expectations, plans and prospects for PTC, our product and product candidates, our commercialization plans with respect to Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy, and the potential advantages of Translarna are forward-looking statements. Our actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements we make as a result of a variety of risks and uncertainties, including those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations
for regulatory approvals, our scientific approach and general development progress, and the factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC's other filings with the
SOURCE
News Provided by Acquire Media